PPD Interpretation Physiopathology background and practice assessmento

Interpretación de la PPD. Fundamentos Fisiopatologicos y enfoque práctico

Published 2007-03-01

Open | Download
PDF (Spanish) FLIP
Issue
Vol. 19 No. 1 (2007)
Section
Revisión de tema
How to Cite
PPD Interpretation Physiopathology background and practice assessmento.
rev. colomb. neumol. [Internet]. 2007 Mar. 1 [cited 2024 Nov. 22];19(1):11-7.
DOI
license
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Ninguna publicación, nacional o extranjera, podrá reproducir ni traducir sus artículos ni sus resúmenes sin previa autorización escrita del editor; sin embargo  los usuarios pueden descargar la información contenida en ella, pero deben darle atribución o reconocimiento de propiedad intelectual, deben usarlo tal como está, sin derivación alguna.

Carlos E Pérez
Medico Infectólogo. Jefe Unidad de Infectologia. Hospital Militar Central.
    Andrés Borda
    Medicina Interna Hospital Militar Central. Universidad Militar Nueva Granada.
      Show authors biography

      Tuberculosis is a public health trouble, and PPD is a tool for latent TB infection detection. The PPD interpretation in a model that include physiopathologic features, immune system and risk factors allow a right decision about treatment of latent TB infection in a high prevalence place. This review is a introduction to a rational PPD interpretation.

      Article visits 117 | PDF visits 2646

      Downloads

      Download data is not yet available.
      1. Lauzardo M, Ashkin. Phthisiology at the dawn of the new century. Chest 2000, 117:1455-73.
      2. Raviglione MC. The TB epidemic from 1992 to 2002. Tubercu- losis 2003;83: 4 -14.
      3. Chaparro PE, García I, Guerrero MI, León CI. Situación de la tuberculosis en Colombia, 2002. Biomédica 2004; 24 (Suppl 1): 102-14.
      4. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000;161:S221–47,
      5. Adams, D, O., and T . Hamilton. The cell biology of macrophage activation. Annual Review of Inmunology 2: 283 -318, 1984.
      6. Dannenberg, A. M., Jr. Delayed-type hypersensitivity and cell. mediated immunity in the pathogenesis of tuberculosis. Immunology Today 1991, 12:229-233.
      7. Mutis T, Cornelisse, Y.E Ottenho T.H.M. (1993). Mycobacteria induce CD4+ T cells that are cytotoxic and display Th1-like cytokines secreting pro¢le: heterogeneity in cytotoxic activity and cytokine secretion levels. Eur. J. Immunol. 23, 2189-2195.
      8. Joint Tuberculosis Committee of the Brithish Thoracic Society. Control and prevention of tuberculosis in the United Kingdom: Code of Practice 2000. Thorax 2000; 55: 887-901.
      9. Robert M J, Payam N, Philip C. Latent Tuberculosis Infection. N.E.J.M 2002, VOL 347;1860 - 1866
      10. Cohn DL. El Sadr WM. Treatment of latent tuberculosis infection. In L. B Reichman and E hershfield ,editors. Tuberculosis: A comprehensive International Aprroach,2nd ed. Marcel Deker. New York. 2000: 471 -502
      11. Ferebee SH et al. An epidemiological model of tuberculosis in the United States: TB control: with present methods? With BCG vaccination? Or with isoniazid prophylaxis? NTA Bulletin 1967; 53 (1) 4 -7.
      12. Van Rie A, Warren R, Richardson M, et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med 1999; 341;1174 -1179.
      13. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000;161:S221–47.
      14. Lowe JC, Beck JS. Gibas JH, et al. Skin test responsiveness to tour new tuberculins in patients with chronic obstructive airways disease receiving short term high doses of, or long term maintenance treatment with prednisolone. J Clin Pathol 1987; 40: 42 – 9.
      15. Nash DR, Douglass JE. Anergy in active pulmonary tuberculosis: a comparación between positive and negative reactors and an evaluation of 5 TU and 250 TU skin test does. Chest 1980; 77: 32-7.
      16. American Thoracic Society. The tuberculin skin test. Am Rev Respir Dis 1981; 124:356–363
      17. Kendig EL Jr, Kirkpatrick BV, Carter H, et al. Under reading of the tuberculin skin test reaction. Chest 1998; 113:1175–1177
      18. Graham N M.H., Nelson K.E, Solomon L , Bonds M., Rizzo RT, Scavotto J, J Astemborski, Vlahov. 1992. Prevalence of tuberculin positivity and skin test anergy in HIV-I seropositive an seronegative intravenous drug users. JAMA. 267:369 – 373.
      19. Whalen CC, Johnson JL, Okwera A, Et al. A trial of Three regimens to prevent tuberculosis un Ugandan adults infected with human immunodeficiency virus. N Engl J Med. 1997; 337: 801 – 808.
      20. Chest variabilidad de la prueba
      21. Janis E M , Allem W D, Glesby J M, et al. Tuberrculin Skin Test Reactivity, Anergy, and HIV Infection in Hospitalized Patients. The American Journal of Medicine. 1996; 100: 186 – 192.
      22. Centers for Disease Control. Purified protein derivative (PPD)- tuberculin anergy and HIV infection: guidelines for anergy testing and management of anergic persons at risk of tuberculosis. MMWR. 1991; 40: 27–33.
      23. Dalal BD , Dalal P, Desai H . Tuberculin test – A Good Tool in HIV Positive Patients. J Allergy Clin Immunol, 2003, Abstracts : 629. S 226.
      24. Centers for Disease Control. Purified protein derivative (PPD)– tuberculin anergy and HIV infection: guidelines for anergy testing and management of anergic persons at risk of tuberculosis. MMWR. 1991; 40: 27 – 33
      25. Centers for Control and prevention. 1997. Anergy skin testing and tuberculosis preventive therapy for VIH infected persons: revised recomenmendations. M.M.W.R. 46 (No. RR -15) : 1 – 10.
      26. Wolfe F, Michaud K, Anderson J, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum. 2004;50:372 – 379.
      27. Keane J, Gershon S, Wine RP, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha – neutralizing agent. N Engl J Med 2001; 345: 1098 – 104.
      28. Slovis BS, Plitman JD, Haas DW. The case against anergy testing as a routine adjunct to tuberculin skin testing . JAMA. 2000; 283: 2003 – 2007.
      29. Menzies T, Vissandjee B. Effect of Bacille Calmette – Guerin Vaccination on tuberculin reactivity. Am Rev Respir Dis 1992; 145: 621 – 5.
      30. Myers JP. New Recommendations for the treatment of tuberculosis. Curr Opin Infect Dis 2005; 18:133 - 40
      31. Woeltje KF, Mathew A. Rothstein M, Seiler S, Fraser VJ. Tuberculosis infection and anergy in hemodiálisis patients. Am J Kidney Dis 1998; 31: 848 – 852.
      32. Taskapan H, Utas C, Oymak S, Gulmez I, Ozesmi M. The outcome of tuberculosis in patients on chronic hemodialysis. Clin Nephrol 2000; 54 (2): 134 – 7
      33. Kuddusi C, Seker A. Boosted Tuberculin skin testing in hemodialysis patients. Am J infect Control 2006;34:383-7.
      34. Ravi Shankar M, Aravindan AN. et al. The prevalence of tuberculin sensitivity and anergy in chronic renal failure in an endemic area: tuberculin test and the risk of post – transplant tuberculosis. Nephrol Dial Transplant (2005) 20:2720 – 2724.
      35. Akiyama M, Numata A, Imagawa A. Influence of protein intake on phytohemagglitinin skin test in patients undergoing maintenance hemodialysis. (abstract) Nippon Hinyokika Gakkai Zasshi 1989; 80: 1175 – 1180.
      36. Ravi Shankar M, Aravindan AN.. et al. The prevalence of tuberculin sensitivity and anergy in chronic renal failure in an endemic area: tuberculin test and the risk of post – transplant tuberculosis. Nephrol Dial Transplant (2005) 20:2720 – 2724.
      37. Menzies D. Interpretation of Repeated Tuberculin Test. Am J Respir Crit Care Med 1999. Vol 159. PP 15 -21,
      38. Cauthen.G.M, Snider DE, Onorato IM. 1994. Boosting of tuberculin sensitivity among Southeast Asian Refugees. Am. J Respir. Crit. Care Med. 149: 1597 – 1600.
      39. Perez – Stable E. J , Slutkin G. 1985 . A demonstration of lack of variability among six tuberculin skin test readers. Am. J Public Health 75: 1341 – 1343
      40. Grzbowski S, Allen EA. The Challenge of tuberculosis in decline: A study based on the epidemiology of tuberculosis in Ontario, Canada. Am Rev Respir Dis. 1964; 90: 707 – 720.
      41. Stead WW. Management of Health care workers after in advertent exposure tuberculosis: A guide for the use the preventive therapy. Ann Intern Med. 1995; 122:906 -912.
      42. Huebner RE, Schein MF, Bass Jr JB. The tuberculin skin test. Clin Infect Dis 1993;17:968–75.
      43. Pouchot J, Grasland A, Collet C, Coste J, Esdaile JM, Vinceneux P. Reliability of tuberculin skin test measurement. Ann Intern Med 1997;126:210–4.
      44. Ozuah PO, Burton W, Lerro KA, Rosenstock J, Mulvihill M.Assessing the validity of tuberculin skin test readings by trained professionals and patients. Chest 1999;116:104–6.
      45. Barnes PF, Bloch AB, Davidson PT, Snider Jr DE. Tuberculosis in patients with human immunodeficiency virus infection. New Engl J Med 1991;324:1644–50.
      46. Dorken E, Grzybowski S, Allen EA. Significance of the protein tuberculin test in the elderly. Chest 1987;92:237–40.
      47. Sahn SA, Lakshminarayan S. Tuberculosis after corticosteroid therapy. Br J Dis Chest (abstract) 1976;70:195–205.
      48. Von Reyn CF, Williams DE, Horsburgh Jr CR et al. Dual skin testing with Mycobacterium avium sensitin and purified protein derivative to discriminate pulmonary disease due to M .avium complex from pulmonary disease due to Mycobacterium tuberculosis. J Infect Dis 1998;177:730–6.

      Information

      Journal history

      Keywords

      QR code

      Funding

      Support + Info: Here

       

       

      Directories and indexes

      Google Scholar profile

      Most read in the last 30 days

      Current Issue

      Sistema OJS 3.4.0.7 - Metabiblioteca |